{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-23-000032","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2023-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.140277+00:00","generated_at":"2026-06-13T02:13:02.748481+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Edwards Q2 sales $1.53B (+11% YoY); adj EPS $0.66; raises FY23 guidance","bullets":["Q2 sales $1.53B (+11%/+12% constant currency); GAAP EPS $0.50 (incl. IP charge), adjusted EPS $0.66.","TAVR sales $992M (+9%/+10% constant currency); TMTT $48M; Surgical $256M; Critical Care $235M.","Raised FY2023 sales guide to $5.9-$6.1B (prior $5.6-$6.0B), constant currency growth 10-13%.","Adjusted EPS guide raised to $2.50-$2.60 (prior $2.48-$2.60); Q3 guide $1.44-$1.52B sales, $0.55-$0.61 adj EPS.","Adjusted gross margin 77.7% (vs 80.5% YoY); $300M IP payment; cash $1.5B, debt $600M."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-23-000032","json":"https://secwatch.observer/filing/0001099800-23-000032.json","markdown":"https://secwatch.observer/filing/0001099800-23-000032.md","text":"https://secwatch.observer/filing/0001099800-23-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000032/0001099800-23-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000032/ew-20230726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:13:02.748481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"74c65a863f3830a0fd107b78dc67b9c1e6e9bbe4","claim":"Edwards Lifesciences Corp updated its second quarter of 2023 guidance (raised).","evidence_excerpt":"On July 26, 2023, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the second quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980023000032/0001099800-23-000032-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}